From microbes to medicine: harnessing the power of the microbiome in esophageal cancer DOI Creative Commons
Xiaoyan Liu, Bang Li, Liping Liang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 12, 2024

Esophageal cancer (EC) is a malignancy with high incidence and poor prognosis, significantly influenced by dysbiosis in the esophageal, oral, gut microbiota. This review provides an overview of roles microbiota EC pathogenesis, emphasizing their impact on tumor progression, drug efficacy, biomarker discovery, therapeutic interventions. Lifestyle factors like smoking, alcohol consumption, betel nut use are major contributors to development. Recent studies utilizing advanced sequencing have revealed complex interactions between EC, oral pathogens such as Porphyromonas gingivalis Fusobacterium nucleatum promoting inflammation suppressing immune responses, thereby driving carcinogenesis. Altered esophageal microbiota, characterized reduced beneficial bacteria increased pathogenic species, further exacerbate local growth. Gut also affects systemic immunity, influencing chemotherapy immunotherapy certain enhancing or inhibiting treatment responses. Microbiota composition shows potential non-invasive for early detection, personalized therapy. Novel strategies targeting microbiota—such probiotics, dietary modifications, fecal transplantation—offer promising avenues restore balance improve potentially patient outcomes. Integrating microbiome-focused into current frameworks could management, reduce adverse effects, enhance survival. These findings highlight need research microbiota-tumor microbial interventions transform prevention, particularly cases late-stage diagnosis response.

Language: Английский

Progress in Drug Delivery Systems Based on Nanoparticles for Improved Glioblastoma Therapy: Addressing Challenges and Investigating Opportunities DOI Open Access
Md. Ataur Rahman, Maroua Jalouli,

Mahesh Kumar Yadab

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(4), P. 701 - 701

Published: Feb. 19, 2025

Glioblastoma multiforme (GBM) is a highly malignant brain tumor that has bleak outlook despite existing treatments such as surgery, radiation, and chemotherapy. The utilization of nanoparticles for drug delivery presents promising method by which to improve the effectiveness treatment while reducing harmful effects on entire body. This review examines application in GBM, focusing different types nanoparticles, including lipid-based, polymeric, metallic, those under development. Every variety analyzed its distinct characteristics therapeutic capacity. Lipid-based liposomes solid lipid enhance transport medicines are not soluble water have shown considerable potential preclinical investigations. Polymeric benefits terms controlled release targeted distribution, whereas metallic both therapy imaging. In current we would like emphasize ways medicine delivery, specifically enhancing penetration blood-brain barrier (BBB), targeting tumors, enabling release. Additionally, also discuss clinical discoveries, highlighting achievements obstacles process converting these technologies into effective GBM. study offers thorough examination present status prospects

Language: Английский

Citations

5
Cell membrane-inspired chitosan nanoparticles for prolonged circulation and tumor-targeted drug delivery DOI
Mingzhu Xie, Jing Zhao, Xikang Feng

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 304, P. 140934 - 140934

Published: Feb. 11, 2025

Language: Английский

Citations

2
A Self‐Amplifying Photodynamic Biomedicine for Cascade Immune Activation Against Triple‐Negative Breast Cancer DOI Open Access

Xianquan Feng,

Yan Zhang,

Wanjing Lin

et al.

Small, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 23, 2025

Abstract The efficacy of immunotherapy in triple‐negative breast cancer (TNBC) is significantly hindered by its low immunogenicity and immunosuppressive tumor microenvironment. Non‐invasive photodynamic therapy (PDT) increasingly recognized as a potential immunotherapeutic stimulant the treatment TNBC. However, constrained hypoxia excessive inflammation suppression during course treatment. Herein, simple efficacious biomedicine formulated to overcome adverse influences amplifying immunotherapy, thereby stimulating systemic immune response. Specifically, approach targeted delivery employing specific agents such photosensitizer (verteporfin), hypoxic ameliorator (atovaquone), cyclooxygenase‐2/prostaglandin E2 (COX‐2/PGE2) signaling blocker (celecoxib). More importantly, effectively ameliorated inhibited COX‐2/PGE2 signaling, PDT‐induced immunogenic cell death. This, turn, enhanced triggered robust response cascade. Notably, self‐amplifying primary tumors, distal lung metastases, post‐operative recurrence while maintaining high biocompatibility. To sum up, work provides viable cascade stimulation an efficient biomedical nanoplatform, offering novel strategy for TNBC clinic.

Language: Английский

Citations

1
Nanostructure-reinforced multifunctional hydrogels for synergistic cancer therapy DOI
Satar Yousefiasl, Mahsa Ghovvati,

Mojdeh Mirshafiei

et al.

Coordination Chemistry Reviews, Journal Year: 2024, Volume and Issue: 522, P. 216207 - 216207

Published: Sept. 13, 2024

Language: Английский

Citations

4
Oncolytic Virus Therapy in a New Era of Immunotherapy, Enhanced by Combination with Existing Anticancer Therapies: Turn up the Heat! DOI Creative Commons

Emily Charlotte Fretwell,

Annwyne Houldsworth

Journal of Cancer, Journal Year: 2025, Volume and Issue: 16(6), P. 1782 - 1793

Published: Feb. 18, 2025

Oncolytic viral therapy is a promising treatment for cancer, where 'cold' tumour cells can become 'hot' to the host immune system. However, with few FDA approved therapies, development of new strategies more cancer types has been slow and relatively unsuccessful in recent years, Combination successful other treatment, therefore, may be viable alternative improve efficacy oncolytic which reduce some adverse events currently used monotherapies, virus chemotherapy being mutually complimentary each other. Combining viruses checkpoint inhibitors provides significant increase when was combined drug ipilimumab. Phase I II studies concluded that combination chemotherapies safe effective but did not significantly on current monotherapies. Recent experiments suggest CAR-T CAR--M therapeutic approach needs advance clinical testing observe human response therapy. Viral ipilimumab showed highest potential trials should advanced phase III find conclusive supporting evidence. This review aims identify evaluate evolving advances genetic engineering providing enhanced activity tumour, addressing lack responses tumours, an additional role enhancing conventional therapies. The 'turn up heat' microenvironment immunogenicity anticancer treatments, future

Language: Английский

Citations

0
Nanoparticle-based Traditional Chinese Medicine for Immunotherapy in Gastrointestinal Tumors DOI Creative Commons

Linjia Peng,

Yan‐Feng Liang,

Qiuli Zhang

et al.

Nano Biomedicine and Engineering, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Advances in cancer nanovaccines: a focus on colorectal cancer DOI
Yalda Ghazizadeh,

Hossein Salehi Shadkami,

Fatemeh Madani

et al.

Nanomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 13

Published: April 5, 2025

Nanotechnology has revolutionized cancer treatment by providing innovative solutions through nanocancer therapies, nanovaccines, and nanoparticles. This review focuses on the application of these technologies in colorectal (CRC), highlighting their progression from preclinical studies to clinical trials. Nanoparticles, including liposomes, silica, gold, lipid nanoparticles, possess unique properties that enhance drug delivery, improve therapeutic efficacy, minimize systemic toxicity. Additionally, nanovaccines are being developed elicit robust immune responses against CRC cells. paper offers a comprehensive overview current state nanotechnology-based treatments for CRC, emphasizing key trials demonstrate potential. Furthermore, discusses challenges faced this field. It outlines future directions research, underscoring need ongoing efforts translate promising into practical applications.

Language: Английский

Citations

0
Chemoimmunotherapy synergism: mechanisms and clinical applications DOI

Rahaman Shaik,

Sai Manasa Chittepu,

Meghana Tarapatla

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: April 12, 2025

Language: Английский

Citations

0
Immunomodulatory nanoplatforms with multiple mechanisms of action in cancer treatment DOI

Raffaella Villa,

Ya‐Ping Shiau,

Sohaib Mahri

et al.

Nanomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 18

Published: May 7, 2025

Cancer immunotherapies have transformed oncology by utilizing the immune system to target malignancies; however, limitations in efficacy and potential side effects remain significant challenges. Nanoparticles shown promise enhancing drug delivery improving activation, with for numerous modifications tailor them specific environments or targets. Integrating nanoplatforms offers a promising avenue overcome these hurdles, treatment outcomes reducing adverse effects. By delivery, targeting, modulation, can unlock full of cancer immunotherapy. This review explores role addressing immunotherapy outcomes, examining various types nanoplatforms. Understanding mechanisms immunomodulation through nanoplatform deliveries is crucial. We discuss how interact tumor microenvironment, modulate tumor-associated macrophages regulatory T cells, activate cells directly, enhance antigen presentation, promote immunological memory. Further benefits include combination approaches integrating chemotherapy, radiotherapy, phototherapy. Immunotherapy relatively new approach, but clinical studies already utilize nanoplatform-based results. aims provide insights into pave way more effective personalized strategies.

Language: Английский

Citations

0
Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation DOI Creative Commons
Ashok Kumar Bishoyi, S Nouri,

Ahmed Abdulahi Hussen

et al.

Clinical and Experimental Medicine, Journal Year: 2025, Volume and Issue: 25(1)

Published: May 17, 2025

Leukemia, a group of blood cancers, presents significant global health challenge. Despite advancements in conventional therapies like chemotherapy and immunotherapy, the need for more effective less toxic treatments remains. Nanotechnology offers promising avenue targeted drug delivery immune modulation fight against leukemia. Through utilization nanomaterials' special qualities, their small size, large surface area, capacity to transport variety payloads, scientists are creating novel ways get around drawbacks treatments. These strategies include delivery, cell activation, overcoming resistance. However, challenges remain translating these nanotechnological approaches into clinical applications. Addressing issues such as toxicity, biodistribution, regulatory hurdles is crucial successful development nanomedicine In conclusion, nanotechnology future treatment Continued research essential unlock full potential nanomaterials improve patient outcomes. The nanotechnology-based effectiveness leukemia explored this review. We go over function different delivering therapeutic agents cells, liposomes, polymeric nanoparticles, inorganic anoparticles. also investigate engineering influence system promote anti-tumor reactions.

Language: Английский

Citations

0